By Colin Kellaher

 

Amgen Inc. (AMGN) Thursday said Repatha will only be available at its lower list price next year as the company works to make the cholesterol drug more affordable.

Amgen last year cut the list price of Repatha by 60% to $5,850 a year in a bid to reduce out-of-pocket costs, especially for Medicare patients.

The Thousand Oaks, Calif., biotechnology company also continued to offer the original list price option of more than $14,000 to minimize disruption in the supply chain and allow time for payers and pharmacy benefit managers to modify existing contracts.

Amgen, which reported $91 million in U.S. Repatha sales for the second quarter, said it will discontinue the Repatha original list price option Dec. 31.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

October 24, 2019 09:38 ET (13:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Amgen Charts.